AU541321B2 - Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives - Google Patents

Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives

Info

Publication number
AU541321B2
AU541321B2 AU16416/83A AU1641683A AU541321B2 AU 541321 B2 AU541321 B2 AU 541321B2 AU 16416/83 A AU16416/83 A AU 16416/83A AU 1641683 A AU1641683 A AU 1641683A AU 541321 B2 AU541321 B2 AU 541321B2
Authority
AU
Australia
Prior art keywords
antibodies
related derivatives
labeled conjugates
digoxigenin
immunogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU16416/83A
Other languages
English (en)
Other versions
AU1641683A (en
Inventor
James Paul Albarella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Publication of AU1641683A publication Critical patent/AU1641683A/en
Application granted granted Critical
Publication of AU541321B2 publication Critical patent/AU541321B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AU16416/83A 1982-09-23 1983-06-30 Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives Ceased AU541321B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/422,217 US4469797A (en) 1982-09-23 1982-09-23 Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US422217 1989-10-16

Publications (2)

Publication Number Publication Date
AU1641683A AU1641683A (en) 1984-03-29
AU541321B2 true AU541321B2 (en) 1985-01-03

Family

ID=23673888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16416/83A Ceased AU541321B2 (en) 1982-09-23 1983-06-30 Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives

Country Status (8)

Country Link
US (1) US4469797A (cg-RX-API-DMAC10.html)
EP (1) EP0104527B1 (cg-RX-API-DMAC10.html)
JP (1) JPS5983056A (cg-RX-API-DMAC10.html)
AU (1) AU541321B2 (cg-RX-API-DMAC10.html)
CA (1) CA1213579A (cg-RX-API-DMAC10.html)
DE (1) DE3369887D1 (cg-RX-API-DMAC10.html)
ES (1) ES525861A0 (cg-RX-API-DMAC10.html)
IL (1) IL69126A0 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588219B2 (en) * 1983-08-16 1989-09-14 Agence Nationale De Valorisation De La Recherche (Anvar) Derivatives of muramyl-peptides and of steroids having macrophage-activating properties

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650771A (en) * 1983-11-04 1987-03-17 Miles Laboratories, Inc. Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
US4595656A (en) * 1984-01-06 1986-06-17 Becton Dickinson & Company Coupling agents and products produced therefrom
US4654311A (en) * 1984-06-15 1987-03-31 Syntex (U.S.A.) Inc. Serum pretreatment for digoxin assay
US4767720A (en) * 1985-08-29 1988-08-30 Hsc Research Development Corporation Antidigoxin antibodies
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
FR2601141A1 (fr) * 1986-07-02 1988-01-08 Centre Nat Rech Scient Produit de couplage a base d'haptene, utile notamment comme substance immunogene, anticorps correspondants et applications
US5034317A (en) * 1987-01-30 1991-07-23 Polaroid Corporation Enzyme controlled release system and organic conjugate reactant
US6326136B1 (en) * 1988-04-01 2001-12-04 Digene Corporation Macromolecular conjugate made using unsaturated aldehydes
DE3836656A1 (de) * 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
CA2031109C (en) * 1990-07-27 1992-01-28 Susan J. Danielson Ligand analogs for immunoassays derived from dicarboxylic acid oxidation products
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
RU2132553C1 (ru) * 1996-05-30 1999-06-27 Ивановская Елена Алексеевна Количественное определение дигоксина в сыворотке крови методом инверсионной вольтамперометрии
WO1998036099A1 (en) * 1997-02-18 1998-08-20 Oncor, Inc. Detection of targets with green fluorescent protein and fluorescent variants thereof
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ATE329622T1 (de) * 1998-04-15 2006-07-15 Lexigen Pharm Corp Steigerung der antikörper-zytokin- fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
RU2262510C9 (ru) * 1999-05-19 2006-04-20 Лексиген Фармасьютикэлс Корп. Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US7517526B2 (en) * 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
EP1366067B1 (en) * 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) * 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
ES2358737T3 (es) * 2002-01-31 2011-05-13 Randox Laboratories Ltd. Inmunógenos, anticuerpos y conjugados para cetamina y sus metabolitos.
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US7935539B2 (en) * 2003-02-14 2011-05-03 Siemens Healthcare Diagnostics, Inc. Generic method for latex agglutination assays
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
JP2005172694A (ja) * 2003-12-12 2005-06-30 Fuji Photo Film Co Ltd タンパク質の検出方法
EP1699822B1 (en) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7 fusion proteins with antibody portions, their preparation and their use
PT1699821E (pt) * 2003-12-31 2012-08-23 Merck Patent Gmbh Proteína de fusão fc-eritropoietina com farmacocinética melhorada
JP2007517506A (ja) * 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) * 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2656347A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
ES2491743T3 (es) 2006-11-01 2014-09-08 Ventana Medical Systems, Inc. Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
US7682789B2 (en) * 2007-05-04 2010-03-23 Ventana Medical Systems, Inc. Method for quantifying biomolecules conjugated to a nanoparticle
EP3561513A1 (en) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
AU2009256349B2 (en) 2008-06-05 2014-06-26 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
WO2010065437A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
WO2010121766A1 (en) * 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
USPP22463P3 (en) * 2010-02-16 2012-01-17 Menachem Bornstein Gypsophila plant named ‘Pearl Blossom’
CA2800936A1 (en) 2010-07-02 2012-01-05 Ventana Medical Systems, Inc. Hapten conjugates for target detection
MX2013007559A (es) * 2011-01-03 2013-07-29 Hoffmann La Roche Composicion farmaceutica de complejo de anticuerpo anti-digoxigenina y digoxigenina que se conjuga a un peptido.
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
EP2912064B1 (en) 2012-10-24 2019-04-24 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
CA3004504A1 (en) 2015-11-06 2017-05-11 Ventana Medical Systems, Inc. Tissue homogenisation for representative diagnostics
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
AU2017241440B2 (en) 2016-03-29 2024-06-27 Board Of Regents, The University Of Texas System Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
CN109195990A (zh) 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
JP7768666B2 (ja) 2017-05-31 2025-11-12 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
CA3081548A1 (en) 2017-09-26 2019-04-04 The Regents Of The University Of California Compositions and methods for treating cancer
WO2019092269A1 (en) 2017-11-13 2019-05-16 F. Hoffmann-La Roche Ag Devices for sample analysis using epitachophoresis
JP7455816B2 (ja) * 2018-09-20 2024-03-26 ヴェンタナ メディカル システムズ， インク． クマリン系架橋試薬
WO2020074742A1 (en) 2018-10-12 2020-04-16 F. Hoffmann-La Roche Ag Detection methods for epitachophoresis workflow automation
CN110174363A (zh) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
US20220325268A1 (en) 2019-05-14 2022-10-13 Roche Sequencing Solutions, Inc Devices and methods for sample analysis
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
US20230106973A1 (en) 2020-02-17 2023-04-06 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3855208A (en) * 1971-05-24 1974-12-17 Becton Dickinson Co Derivatives of digoxigenin
US3953431A (en) * 1971-05-24 1976-04-27 Becton, Dickinson & Company Derivatives of digoxigenin
GB1441101A (en) * 1972-06-22 1976-06-30 Wellcome Found Reagents for the assay of cardenolide glycosides and aglycones
US4064227A (en) * 1975-03-17 1977-12-20 Mallinckrodt, Inc. Radioimmunoassay method for the determination of cardiotonic glycosides
FR2310766A1 (fr) * 1975-05-16 1976-12-10 Nativelle Sa Ets Derives de cardenolides, procede de preparation et application a titre de medicament
US4082747A (en) * 1975-10-01 1978-04-04 Mallinckrodt, Inc. Chemical process
JPS53119873A (en) * 1977-03-28 1978-10-19 Rohm & Haas Digoxigenin derivative
CA1119163A (en) * 1977-09-01 1982-03-02 Ravi K. Varma Digoxigenin derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588219B2 (en) * 1983-08-16 1989-09-14 Agence Nationale De Valorisation De La Recherche (Anvar) Derivatives of muramyl-peptides and of steroids having macrophage-activating properties

Also Published As

Publication number Publication date
CA1213579A (en) 1986-11-04
ES8601478A1 (es) 1985-11-01
EP0104527A1 (en) 1984-04-04
JPS5983056A (ja) 1984-05-14
AU1641683A (en) 1984-03-29
JPH0231346B2 (cg-RX-API-DMAC10.html) 1990-07-12
US4469797A (en) 1984-09-04
ES525861A0 (es) 1985-11-01
EP0104527B1 (en) 1987-02-25
IL69126A0 (en) 1983-10-31
DE3369887D1 (en) 1987-04-02

Similar Documents

Publication Publication Date Title
AU541321B2 (en) Digoxigenin immunogens, antibodies, labeled conjugates and related derivatives
AU589635B2 (en) Antibody conjugates
AU554345B2 (en) Tricyclic antidepressant drug immunogens, antibodies labelled conjugates, and related derivatives
AU590462B2 (en) Immunoglobulin conjugates
AU2589984A (en) Galactosyl-insulin conjugates
AU541679B2 (en) Ergolinyl -n:,n:-diethylurea derivatives
AU7334987A (en) Immunoglobulin conjugates
AU572792B2 (en) 2-amino, 4-oxo-pteridine derivatives
AU2274783A (en) Pyridine derivatives
DE3471756D1 (en) Immunogens, antibodies, labeled conjugates, and related derivatives for lidocaine and analogs thereof
AU2222083A (en) Pyridine derivatives
AU566419B2 (en) U/,3-oxazoliding-2-one derivatives
AU563950B2 (en) 2,2 -disubstituted-1,3-oxepine derivatives
AU1288188A (en) Immunoglobulin conjugates
AU4724385A (en) Elektrodanordning for vattenrenare enligt jonisations- principen, foretradesvis for simbassanger
AU1575383A (en) 1,4-dihyropyridine derivatives
AU6881081A (en) Substituted-2,4,5-triarylthiazole derivatives
AU565538B2 (en) 3,3-dialkyl indoline derivatives
AU568295B2 (en) 1,2,4-triazol-i-yl-propionitrile derivatives
AU534679B2 (en) Steroid immunogens
AU2277283A (en) Pyridyloxybenzanilide derivatives
AU544710B2 (en) Disopyramide immunogens, antibodies and labelled conjugates
AU556771B2 (en) Cyclohexeny pyridine derivatives
AU546925B2 (en) 3-acetyl-4-oxo-2,2-azetidine-dicarboxylate derivatives
AU636164B2 (en) 2,3-dihydro-1-hydroxy-3-oxo-2-(1-substituted-4-piperidinyl)- 1N-isoindole derivatives